← Eichor
Study identifier: NCT05576974 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

Condition: Head and Neck Cancer · Unknown Primary Cancer · Head and Neck Squamous Cell Carcinoma  ·  Sponsor: University of Texas Southwestern Medical Center

PhasePhase 2
Planned participants120
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.

This description comes directly from the study's public registry record.

Talk to the study team

Baran Sumer, MD  ·  2146482904  ·  Baran.Sumer@UTSouthwestern.edu

Sindhu Voorugonda, MBBS  ·  2146488096  ·  Sindhunikhila.voorugonda@utsouthwestern.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Texas Southwestern Medical CenterDallas, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05576974